Les patients avec antécédents d'allergies ou d'insuffisance rénale sont plus à risque.
Facteurs de risqueAllergiesInsuffisance rénale
#2
Les personnes âgées sont-elles plus vulnérables ?
Oui, elles peuvent avoir une fonction rénale diminuée, augmentant le risque d'effets indésirables.
Personnes âgéesFonction rénaleVulnérabilité
#3
Les patients diabétiques sont-ils à risque ?
Oui, le diabète peut affecter la fonction rénale, augmentant le risque de complications.
DiabèteInsuffisance rénaleComplications
#4
Y a-t-il des risques pour les femmes enceintes ?
Oui, l'utilisation doit être évitée sauf en cas de nécessité, en raison des risques potentiels.
Femmes enceintesRisquesContre-indications
#5
Les antécédents d'allergies augmentent-ils le risque ?
Oui, les patients avec des antécédents d'allergies aux agents de contraste sont à risque accru.
Antécédents d'allergiesAgents de contrasteFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Acide gadopentétique : Questions médicales les plus fréquentes",
"headline": "Acide gadopentétique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Acide gadopentétique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-26",
"dateModified": "2026-06-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Acide gadopentétique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Complexes de coordination",
"url": "https://questionsmedicales.fr/mesh/D056831",
"about": {
"@type": "MedicalCondition",
"name": "Complexes de coordination",
"code": {
"@type": "MedicalCode",
"code": "D056831",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.257"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Acide gadopentétique",
"alternateName": "Gadolinium DTPA",
"code": {
"@type": "MedicalCode",
"code": "D019786",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Olivier Grémy",
"url": "https://questionsmedicales.fr/author/Olivier%20Gr%C3%A9my",
"affiliation": {
"@type": "Organization",
"name": "Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France."
}
},
{
"@type": "Person",
"name": "Jennifer S McDonald",
"url": "https://questionsmedicales.fr/author/Jennifer%20S%20McDonald",
"affiliation": {
"@type": "Organization",
"name": "From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905."
}
},
{
"@type": "Person",
"name": "Robert J McDonald",
"url": "https://questionsmedicales.fr/author/Robert%20J%20McDonald",
"affiliation": {
"@type": "Organization",
"name": "From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905."
}
},
{
"@type": "Person",
"name": "Henning Richter",
"url": "https://questionsmedicales.fr/author/Henning%20Richter",
"affiliation": {
"@type": "Organization",
"name": "From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.)."
}
},
{
"@type": "Person",
"name": "Uwe Karst",
"url": "https://questionsmedicales.fr/author/Uwe%20Karst",
"affiliation": {
"@type": "Organization",
"name": "From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Species-dependent uptake of gadolinium in Chlamydomonas reinhardtii algae.",
"datePublished": "2023-09-07",
"url": "https://questionsmedicales.fr/article/37689191",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2023.166909"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis.",
"datePublished": "2023-10-06",
"url": "https://questionsmedicales.fr/article/37832198",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejrad.2023.111146"
}
},
{
"@type": "ScholarlyArticle",
"name": "Near-cure in patients with Gadolinium deposition disease undergoing intravenous DTPA chelation.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39118832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/ftox.2024.1371131"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development and validation a radiomics nomogram for predicting thymidylate synthase status in hepatocellular carcinoma based on Gd-DTPA contrast enhanced MRI.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37848807",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-023-11096-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lobe-Based Hepatic Uptake Index of Gd-EOB-DTPA on Contrast-Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B-Related Cirrhosis.",
"datePublished": "2024-06-21",
"url": "https://questionsmedicales.fr/article/38947874",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2024/6623848"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Complexes de coordination",
"item": "https://questionsmedicales.fr/mesh/D056831"
},
{
"@type": "ListItem",
"position": 4,
"name": "Acide gadopentétique",
"item": "https://questionsmedicales.fr/mesh/D019786"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Acide gadopentétique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Acide gadopentétique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-25",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Acide gadopentétique",
"description": "Quel est le rôle de l'acide gadopentétique en IRM ?\nQuand utilise-t-on l'acide gadopentétique ?\nL'acide gadopentétique est-il sûr pour tous les patients ?\nComment l'acide gadopentétique est-il administré ?\nQuels types d'examens nécessitent cet agent de contraste ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Acide gadopentétique",
"description": "Quels effets secondaires peuvent survenir ?\nComment reconnaître une réaction allergique ?\nL'acide gadopentétique peut-il causer des douleurs ?\nY a-t-il des symptômes graves à surveiller ?\nPeut-on avoir des effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Acide gadopentétique",
"description": "Comment prévenir les réactions allergiques ?\nQuelles précautions pour les patients rénaux ?\nDes tests sont-ils nécessaires avant l'IRM ?\nComment informer les patients des risques ?\nY a-t-il des recommandations pour les femmes enceintes ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Acide gadopentétique",
"description": "Que faire en cas de réaction allergique ?\nComment traiter une douleur au site d'injection ?\nY a-t-il un antidote pour l'acide gadopentétique ?\nComment gérer une insuffisance rénale après administration ?\nDes traitements préventifs existent-ils ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Acide gadopentétique",
"description": "Quelles sont les complications possibles ?\nComment gérer une néphrotoxicité ?\nY a-t-il un risque de fibrose systémique néphrogénique ?\nQuels signes indiquent une complication ?\nComment prévenir les complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Acide gadopentétique",
"description": "Qui est à risque d'effets secondaires ?\nLes personnes âgées sont-elles plus vulnérables ?\nLes patients diabétiques sont-ils à risque ?\nY a-t-il des risques pour les femmes enceintes ?\nLes antécédents d'allergies augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D019786#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quel est le rôle de l'acide gadopentétique en IRM ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il améliore le contraste des images en augmentant la visibilité des structures internes."
}
},
{
"@type": "Question",
"name": "Quand utilise-t-on l'acide gadopentétique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé lors d'examens IRM pour détecter des anomalies comme des tumeurs."
}
},
{
"@type": "Question",
"name": "L'acide gadopentétique est-il sûr pour tous les patients ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il peut être contre-indiqué chez les patients avec insuffisance rénale sévère."
}
},
{
"@type": "Question",
"name": "Comment l'acide gadopentétique est-il administré ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par injection intraveineuse avant ou pendant l'IRM."
}
},
{
"@type": "Question",
"name": "Quels types d'examens nécessitent cet agent de contraste ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour des IRM cérébrales, abdominales et musculosquelettiques."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques, des nausées ou des douleurs au site d'injection peuvent se produire."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent éruption cutanée, démangeaisons, ou difficulté à respirer."
}
},
{
"@type": "Question",
"name": "L'acide gadopentétique peut-il causer des douleurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs au site d'injection ou des maux de tête peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme un gonflement du visage ou des difficultés respiratoires nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des effets à long terme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets à long terme sont rares, mais des études sont en cours sur la toxicité du gadolinium."
}
},
{
"@type": "Question",
"name": "Comment prévenir les réactions allergiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation préalable des antécédents allergiques est cruciale avant l'administration."
}
},
{
"@type": "Question",
"name": "Quelles précautions pour les patients rénaux ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer la fonction rénale et envisager des alternatives si l'insuffisance est présente."
}
},
{
"@type": "Question",
"name": "Des tests sont-ils nécessaires avant l'IRM ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests de fonction rénale peuvent être requis pour certains patients."
}
},
{
"@type": "Question",
"name": "Comment informer les patients des risques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournir des informations claires sur les effets secondaires et les risques potentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les femmes enceintes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation doit être évitée sauf en cas de nécessité absolue et après évaluation des risques."
}
},
{
"@type": "Question",
"name": "Que faire en cas de réaction allergique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut administrer des antihistaminiques et, si nécessaire, des corticostéroïdes."
}
},
{
"@type": "Question",
"name": "Comment traiter une douleur au site d'injection ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Appliquer de la glace et prendre des analgésiques en cas de douleur persistante."
}
},
{
"@type": "Question",
"name": "Y a-t-il un antidote pour l'acide gadopentétique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, mais un traitement symptomatique est recommandé."
}
},
{
"@type": "Question",
"name": "Comment gérer une insuffisance rénale après administration ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance étroite et une hydratation adéquate sont essentielles après l'examen."
}
},
{
"@type": "Question",
"name": "Des traitements préventifs existent-ils ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des protocoles de pré-médication peuvent être envisagés pour les patients à risque."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques sévères et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Comment gérer une néphrotoxicité ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance de la fonction rénale et une hydratation adéquate sont essentielles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de fibrose systémique néphrogénique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ce risque est accru chez les patients avec insuffisance rénale sévère."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme un gonflement, des douleurs abdominales ou des éruptions cutanées doivent alerter."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation rigoureuse des antécédents médicaux et une surveillance post-examen sont cruciales."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec antécédents d'allergies ou d'insuffisance rénale sont plus à risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus vulnérables ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir une fonction rénale diminuée, augmentant le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les patients diabétiques sont-ils à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut affecter la fonction rénale, augmentant le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les femmes enceintes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation doit être évitée sauf en cas de nécessité, en raison des risques potentiels."
}
},
{
"@type": "Question",
"name": "Les antécédents d'allergies augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des antécédents d'allergies aux agents de contraste sont à risque accru."
}
}
]
}
]
}
From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905.
From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905.
From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.).
From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.).
Department of Biomedical Engineering, Michigan State University, East Lansing, MI, United States.
Division of Synthetic Biology, The Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI, United States.
Department of Biomedical Engineering, Michigan State University, East Lansing, MI, United States.
Division of Synthetic Biology, The Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI, United States.
Department of Radiology, Michigan State University, East Lansing, MI, United States.
From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905.
From the Departments of Radiology (J.A., J.S.M., M.A.C., C.R.F., S.H., D.R.J., B.S., G.T., D.D., R.K., D.F.K., R.J.M.), Molecular Pharmacology and Experimental Therapeutics (K.M.W., D.S.C.), Biochemistry and Molecular Biology (J.L.S.), Laboratory Medicine and Pathology (P.J.J., J.A.B.), and Neurosurgery, College of Medicine (D.F.K.), Mayo Clinic, 200 1st St SW, Rochester, MN 55905.
From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.).
From the Diagnostic Imaging Research Unit, Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services (H.R.), Clinic for Zoo Animals, Exotic Pets and Wildlife (L.F.M.), and Musculoskeletal Research Unit, Department of Molecular Mechanisms of Disease (A.K.), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland; Clinic for Neuroradiology, University Hospital Bonn, Bonn, Germany (H.R., A.R.); Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (P.B., C.D., S.F., M.S., U.K.); Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Bonn, Germany (A.R.); and Institute of Neuropathology, University Hospital Münster, Münster, Germany (A.X., A.J.).
Single cell-inductively coupled plasma-mass spectrometry (sc-ICP-MS) was used in this study as a valuable tool to assess the species-dependent uptake of metallopharmaceuticals into algal cells. Chlamy...
The purpose of this study was to establish a model for predicting the prognosis of patients with microvascular invasion (MVI)-negative hepatocellular carcinoma (HCC) based on qualitative and quantitat...
Consecutive patients with MVI-negative HCC who underwent preoperative Gd-EOB-DTPA MRI between January 2015 and December 2019 were retrospectively enrolled.In total, 122 patients were randomly assigned...
During a median follow-up period of 58.86 months, 38 patients (31.15 %) experienced recurrence. Multivariate analysis revealed that lower relative enhancement ratio (RER), hepatobiliary phase hypointe...
The model integrating qualitative and quantitative imaging parameters and clinical parameters satisfactorily predicted the prognosis of patients with MVI-negative HCC....
To demonstrate and evaluate factors contributing to near-cures in patients with Gadolinium Deposition Disease (GDD) undergoing intravenous (IV) DTPA chelation....
Patients who had undergone or are currently undergoing DTPA chelation for GDD were included in this report based on their medical records that showed their perceived improvement was at least 80% back ...
The most common factor was the administration of ≤5 lifetime doses of a Gadolinium-Based Contrast Agents (GBCA) (12/14). Unconfounded agents triggering GDD were seen in nine subjects. Most subjects (1...
Subjects with GDD can experience near-cure with IV DTPA chelation. Factors surveyed that predict near-cure include the start of chelation in the first year, few GBCA administrations, and good health s...
The purpose of this study was to develop and validate a radiomics nomogram for predicting thymidylate synthase (TYMS) status in hepatocellular carcinoma (HCC) by using Gd-DTPA contrast enhanced MRI....
We retrospectively enrolled 147 consecutive patients with surgically confirmed HCC and randomly allocated to training and validation set (7:3). The TYMS status was immunohistochemical determined and c...
A total of 2260 features were extracted and reduced to 7 features as the most important discriminators to build the Rad score. InAFP was identified as the only independent clinical factors for TYMS st...
The radiomics nomogram shows favorable predictive efficacy for TYMS status in HCC, which might be helpful for the personalized treatment of HCC....
To use hepatic uptake index (HUI) of liver lobes on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) to discriminate between patients...
Forty-four consecutive patients with hepatitis B-related cirrhosis who underwent Gd-EOB-DTPA-enhanced MRI were divided into compensated and decompensated statuses based on clinical evaluation. Volume ...
Compensated and decompensated liver cirrhosis were confirmed in 25 (56.82%) and 19 (43.18%) patients, respectively. According to Spearman's rank correlation analysis, RHUI, MHUI, LHUI, and CHUI were a...
The RHUI could help quantitatively discriminate hepatitis B-related cirrhosis between compensated and decompensated statuses....
To develop and validate a nomogram model based on Gd-EOB-DTPA enhanced MRI for differentiation between hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity...
A total of 75 patients with 49 HCCs and 26 FNHs randomly divided into a training cohort (n = 52: 34 HCC; 18 FNH) and an internal validation cohort (n = 23: 15 HCC; 8 FNH). A total of 37 patients (n = ...
In the training cohort, gender, age, enhancement rate in the arterial phase (AP), focal defects in uptake were significant predictors for HCC showing iso- or hyperintensity in the HBP. In the training...
Gd-EOB-DTPA enhanced MRI nomogram model may be useful for discriminating HCC and FNH showing iso- or hyperintensity in the HBP before surgery....
Coronary computed tomography angiography (CCTA) offers non-invasive diagnostics of the coronary arteries. Vessel evaluation requires the administration of intravenous contrast. The purpose of this stu...
A dynamic circulating phantom containing a three-dimensional-printed model of the thoracic aorta and the coronary arteries were used to evaluate injection protocols using gadopentetate dimeglumine at ...
The highest coronary attenuation (441 ± 23 HU, mean ± standard deviation) and CNR (29.5 ± 1.5) was achieved at 40 keV and at the highest GBCA dose (200%). There was a systematic decline of attenuation...
Current PCD-CT protocols and settings are unsuitable for the use of GBCA for CCTA at clinically approved doses. Future advances to the PCD-CT system including a 4-threshold mode, as well as multi-mate...
Patients allergic to iodine-based contrast media and the future of multicontrast CT examinations would benefit greatly from alternative contrast media, but the utility of GBCA for coronary photon-coun...
GBCA-enhanced coronary PCD-CT angiography is not feasible at clinically approved doses. GBCAs have potential applications for the visualization of larger vessels, such as the aorta, on PCD-CT angiogra...
To evaluate the reliability of signal intensity (SI) changes in the basal ganglia as a supposed indicator of gadolinium deposition in the brain after repetitive application of gadolinium-based contras...
One hundred and eight neuropediatric patients (54 male, 54 female, 0-17 years old), with repetitive GBCA-enhanced cranial MRIs between 2003 and 2017, were retrospectively analyzed. Two radiologists me...
The inter-reader agreement was good for GPT and NDP in the whole collective (ICC = 0.837 and ICC = 0.793) and for children >2 years of age (ICC = 0.874 and ICC = 0.790), but poor to moderate for child...
Measurements of SI changes in the basal ganglia are not a reliable parameter with which to evaluate or estimate gadolinium deposition in the brain or to identify suspicious influential factors after r...
Gadolinium-based contrast agents (GBCAs) have been used for more than 30 years to improve magnetic resonance imaging, a crucial tool for medical diagnosis and treatment monitoring across multiple clin...
Gadolinium-based contrast agents (GBCAs) are commonly used in medical imaging. Most intravenously (IV) administered gadolinium is excreted via the kidneys, and pathological retention in renal failure ...